Cerevel Therapeutics price target lowered to $41 from $45 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Cerevel Therapeutics to $41 from $45 and keeps a Buy rating on the shares. The analyst is “disappointed” that due to lower than expected enrollment in the U.S., and delays in the start-up of certain outside the U.S. sites, data from the potentially registrational studies for emraclidine in schizophrenia, re now expected in the second half of 2024.